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The impact of cholesterol and diﬀerent classes of lipoproteins on the development of coronary artery disease (CAD) has been
investigated in extensively during the past 50 years. The cholesterol metabolism is dependent on numerous factors, including
dietary fat, fractional absorption of dietary cholesterol, tissue stores of cholesterol, endogenous cholesterol synthesis, and fecal
bile excretion. Several studies showed signiﬁcantly lower amounts of bile acid secretion in adult patients with CAD compared to
non-CAD patients. Could it be that the inability to eﬃciently excrete bile acids may lead to CAD development?
1.Introduction
While a great deal of attention has been given to the factors
thatdeterminecholesterolhomeostasis,cholesterolexcretion
via bile in patients with CAD has not been thoroughly exam-
ined [1–3].
Clinically, it became obvious that, despite eﬀective cho-
lesterol-modulating treatment (e.g., statins), the develop-
ment of atherosclerosis cannot be stopped in a signiﬁcant
number of patients. It is known that cholesterol is mainly
eliminated from the body via the liver in the form of
bile acids [2, 4, 5]. Therefore, in addition to statins, low-
density lipoprotein cholesterol (LDL-c) can be reduced by
increasing the fecal bile acid waste and by compensatory
hepatic upregulation of bile acid synthesis [2, 4].
It is reasonable to speculate that a reduced ability
to convert cholesterol to bile acids would lead to body
cholesterol overload, with the subsequent development of
atherosclerosis [6–10]. The aim of this paper is to emphasize
the eﬀect of bile acid disposal on coronary artery atheroscle-
rosis.
2.Bile AcidExcretionandIts Relationship
to Coronary Atherosclerosis
2.1. Animal Studies. Studies in animals have revealed that
rodents do not develop experimental atherosclerosis, despite
ingestion of a cholesterol-rich diet [2, 11–13]. They were
able to react to the overload of cholesterol intake by
excreting large amounts of bile acids. The same results were
obtained in a study on New Zealand white rabbits and
primates which were also fed a cholesterol-rich diet [14].
Animals that excreted large amounts of cholesterol did not
develop hypercholesterolemia, whereas those with a less
eﬃcient excretion had increased plasma level of cholesterol
[14]. Furthermore, the degree of hypercholesterolemia was
inversely correlated to the rate of bile acid elimination. These
animal experiments suggest that the atherogenic eﬀect of
the cholesterol-rich diet closely depends on the animal’s
ability to eliminate cholesterol in the form of bile acids
[12, 13]. It is therefore reasonable to speculate that reduced
ability to convert cholesterol to bile acids would lead to
cholesterol overload, with the possibility of subsequent
enhanced development of atherosclerosis [6–10]. A similar
correlation between the elimination of cholesterol in bile
and the development of atherosclerosis was suggested for
humans.
2.2. Human Studies. In an earlier investigation the elimina-
tion of bile acid in the feces of patients who had ischemic
heart disease was compared with that of healthy controls on
the same diet [15]. It was reported that the patients excreted
much fewer bile acids than the controls [15].2 International Journal of Vascular Medicine
Several new studies had shown an inverse relationship
between CAD and bile acid excretion [6–10, 16, 17]. There
are few human studies dealing with disturbed metabolism of
plant sterols (which reﬂects cholesterol) in postmenopausal
CAD women who showed disturbed synthesis and disturbed
secretion of bile acids [15, 16].
These ﬁndings support the hypothesis that CAD patients
produce fewer bile acids than individuals without CAD and
that reduced production of bile acids could lead to advanced
atherosclerosis. These ﬁndings are in line with those of the
several human studies that showed increased fecal excretion
of bile acids to have protective eﬀect on CAD development
[6–10, 15–17]. Most of those investigations were done
on selected populations using the method described by
Grundy et al. [18] for determination of total bile acids.
For example, Simonen and Miettinen [19] showed that
m a l e sw i t hh e t e r o z y g o u sf a m i l i a lh y p e r c h o l e s t e r o l e m i a( F H )
and CAD excreted less bile acids than control males with
FH and normal coronaries. Rajaratnam et al. showed that
postmenopausal women with CAD had ineﬃcient fecal
elimination of cholesterol [17].
We recently published a study on a general adult popu-
lation with and without CAD and found that CAD patients
eliminated subnormal amounts of fecal bile acids [3].
CAD patients excreted 358 ±156mg of total bile acids in
comparison to healthy patients 617 ± 293mg; P<0.01. The
diﬀerencesinexcretionweremainlyduetolowerexcretionof
deoxycholic (188.29 ± 98.12mg versus 325.96 ± 198.57mg;
P<0.0001) and less lithocholic acid (115.43 ± 71.89mg
versus 197.27 ± 126.87mg; P<0.01). Findings of this study
based on 36 CAD patients and 37 non-CAD patients with a
follow-upperiodofupto13yearssupportedearlieronesand
allowedforthereachingofmoreﬁrmconclusionsontherole
oftheeliminationoffecalbileacidsinCADdevelopment[3].
3. Relationship between Plasma Triglycerides,
HDL-Cholesterol,and Bile Acids
HDL-c has been proposed to serve as preferential precursor
for bile acid biosynthesis in the liver. Furthermore, a negative
relationship between plasma levels of HDL cholesterol and
biliary saturation with cholesterol has been reported in
healthy females [20].
In contrast to total cholesterol, LDL-c and HDL-c, there
was a correlation between plasma triglycerides and bile
acid excretion, but only in the non-CAD group [3]. This
can be explained by a rapid and more complete intestinal
absorption of triglycerides due to an excess of bile acids
which are necessary for the emulsiﬁcation of fats. CAD
patients did not exhibit this eﬀect because the amount of
excreted bile acids was signiﬁcantly lower [3].
4.Stroke and Bile Acids Excretion
Atherosclerosis is a disease characterized by lipid accumu-
lation in the vascular wall leading to myocardial infarction
or stroke [20–22]. In spite of proven eﬃcacy of the existing
drugs, like statins, cardiovascular diseases still remain the
most important causes of morbidity and mortality in in-
dustrialized countries. A cholesterol-lowering eﬀect can be
achieved by reducing cholesterol synthesis or by increasing
fecal excretion of bile acids (ileal sodium-dependent bile acid
transporter inhibitors). It is important to emphasize that the
abilitytoexcretelargeamountsofbileacidsnotonlyprevents
CAD development but also may also prevent atherosclerosis
in the cerebral arteries as well [3, 21, 22].
The results of the recent study after a long followup
pointed out to a 6-fold higher incidence of ischemic stroke
among the CAD patients compared to the non-CAD pa-
tients, 7 patients (19%) versus 1 patient (2.7%), and three-
fold greater mortality in the CAD group, 9 patients (25%)
versus 3 patient (8%) [3].
5. 7-α Hydroxylase:The MainEnzyme
Responsible for Bile Acids Excretion
The 7-α hydroxylase is the key enzyme in the conversion
of cholesterol to bile acids [12, 13, 21, 23, 24]. It mediates
the elimination of cholesterol from the plasma and the
intracellular compartment, and it facilitates the excretion
of bile acids. Thus, enhanced excretion of bile acids in
non-CAD individuals can possibly be explained mainly by
increased activity and concentration of 7-α-hydroxylase [12,
13, 21, 23, 24]. In contrast to it, CAD patients are unable
to eﬀectively increase the activity and concentration of 7-α-
hydroxylase [23].
6. FuturePerspective:Combined Treatment
withStatinsandBile AcidSequestrants
A signiﬁcant percentage of patients develop atherosclerosis
despite statin treatment and suppressed levels of choles-
terol. We reason that, by decreasing cholesterol synthe-
sis and increasing the utility of cholesterol, an additive
antiatherosclerosis eﬀect might be achieved. This is partic-
ularly true in the case of patients at high risk for CAD. To
date it is established that these patients require aggressive
lipid-lowering therapy. By combining a statin with drugs
aﬀecting bile acid and cholesterol absorption an optimal
management of dyslipidemia may potentially be ensured.
Additional studies are necessary to validate our contention.
7. Conclusion
Reviewing of several human studies revealed signiﬁcantly
lower excretion of bile acid in adult patients with CAD com-
pared to non-CAD individuals. The diminished excretion of
bile acids might be an independent risk factor for CAD and
a potential target for cholesterol lowering treatment.
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